ReviewAsian journal of andrology2013
The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing.
Review in Asian journal of andrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Value of microRNA-375 as Future Biomarker for Prostate Cancer Detection: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Article
- Changpingibacter yushuensis gen. nov., sp. nov., isolated from fluvial sediment in Qinghai Tibet Plateau of China.Journal of microbiology (Seoul, Korea) · 2022Article
- Rice LEAFY COTYLEDON1 Hinders Embryo Greening During the Seed Development.Frontiers in plant science · 2022Article
- Agromyces laixinhei sp. nov. isolated from bat feces in China.Journal of microbiology (Seoul, Korea) · 2021Article
- Overview of research on fusion genes in prostate cancer.Translational cancer research · 2020Review
- New Insights into the Role of Polybromo-1 in Prostate Cancer.International journal of molecular sciences · 2019Article
- Inhibition of Triple-Negative Breast Cancer Cell Aggressiveness by Cathepsin D Blockage: Role of Annexin A1.International journal of molecular sciences · 2019Article
- Discovery and annotation of a novel transposable element family in Gossypium.BMC plant biology · 2018Article
- Article
- Article
- Mechanisms of Therapeutic Resistance in Prostate Cancer.Current oncology reports · 2017Review
- Article
- Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer.Scientific reports · 2016Article
- Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Review
- A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors.Clinical and translational medicine · 2016Article
- Association of vitamin D receptor variants with clinical parameters in prostate cancer.SpringerPlus · 2016Article
- Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.Biology of the cell · 2015Article
- Evaluation of hGM-CSF/hTNFα surface-modified prostate cancer therapeutic vaccine in the huPBL-SCID chimeric mouse model.Journal of hematology & oncology · 2015Article
- Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.Genome biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prostate cancer is a leading cause of global cancer-related death but attempts to improve diagnoses and develop novel therapies have been confounded by significant patient heterogeneity. In recent years, the application of next-generation sequencing to hundreds of prostate tumours has defined novel molecular subtypes and characterized extensive genomic aberration underlying disease initiation and progression. It is now clear that the heterogeneity observed in the clinic is underpinned by a molecular landscape rife with complexity, where genomic rearrangements and rare mutations combine to amplify transcriptomic diversity. This review dissects our current understanding of prostate cancer 'omics', including the sentinel role of copy number variation, the growing spectrum of oncogenic fusion genes, the potential influence of chromothripsis, and breakthroughs in defining mutation-associated subtypes. Increasing evidence suggests that genomic lesions frequently converge on specific cellular functions and signalling pathways, yet recurrent gene aberration appears rare. Therefore, it is critical that we continue to define individual tumour genomes, especially in the context of their expressed transcriptome. Only through improved characterisation of tumour to tumour variability can we advance to an age of precision therapy and personalized oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.